Harnessing deep learning
to prevent blindness
Learn how Eyenuk can help
Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma
The approval allows Eyenuk’s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31, 2023 – Eyenuk, a global…
Eyenuk named 2022 UCSF Digital Health Awards Finalist
Rising Star Clinical Diagnostic Tool Category Eyenuk has been named a finalist in the Rising Star Clinical Diagnostic Tool category of the UCSF Digital Health Awards. Produced by the University of California at San Francisco’s…
Eyenuk secures $26 Million Series A funding to accelerate global access to AI-powered eye-screening technology
Brings Eyenuk’s total funding to over $43 million Funding round led by AXA IM Alts; joined by T&W Medica A/S, Kendall Capital Partners, and others Eyenuk adds three new board members Funding affirms Eyenuk’s standing…
Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Far Greater Sensitivity than Ophthalmologists’ Dilated Exams
Academic leaders will review their experience with the technology during a symposium at AAO 2022, the American Academy of Ophthalmology annual meeting CHICAGO, September 30, 2022 — From the American Academy of Ophthalmology’s 126th annual…
Vision Loss Rehabilitation Canada brings AI-driven diabetic eye screening to rural and Indigenous communities
Program selects Eyenuk’s EyeArt AI system to make vision-saving screening more accessible in remote Ontario communities LOS ANGELES and TORONTO, August 16, 2022 – Vision Loss Rehabilitation Canada (VLRC), Canada’s leading provider of rehabilitation therapy…
Introducing EyeArt®
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.
Our Product Suite
Products under development. Click here to know more.
* EyeMark™, EyeRead™UWF, EyeSee™AMD, EyeSee™Glaucoma have not yet been cleared for sales in any region.
Eyenuk in the news
